RxDoctor Payments Data

Thomas Patnaude, MD

Internal Medicine · Worcester, MANPI 1316994049

Payments from drug & device makers

$8,073in general payments, 2019–2025

Across 368 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$858
  • Novartis$676
  • Lilly USA, LLC$610
  • AbbVie$496
  • Teva Pharmaceuticals USA, Inc.$471
  • Astellas Pharma US Inc$364
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$7,88898%
  • Education$1852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,073 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$52,999
Medicare patients
126
Services billed
750

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban546$228,924
JardianceEmpagliflozin120$61,039
MounjaroTirzepatide49$50,856
Invega SustennaPaliperidone Palmitate16$36,984
TrulicityDulaglutide33$32,295
TradjentaLinagliptin56$30,218
XareltoRivaroxaban61$28,271
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$28,113
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$24,064
FarxigaDapagliflozin Propanediol39$23,775
EntrestoSacubitril/Valsartan46$20,931
Breo ElliptaFluticasone/Vilanterol36$19,642
Repatha SureclickEvolocumab29$17,161
MyrbetriqMirabegron56$16,830
JanuviaSitagliptin Phosphate24$14,848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$311$228,924546 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$269$102,300197 claims
Lilly USA, LLCMounjaro, Trulicity, Olanzapine$610$89,078237 claims
Johnson & JohnsonInvega Sustenna, Xarelto$297$65,25677 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$286$63,623103 claims
AstraZenecaBreztri Aerosphere, Farxiga$858$47,83976 claims
NovartisEntresto$676$20,93146 claims
Astellas Pharma US IncMyrbetriq$364$16,83056 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →